Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment